AI-Pathway Companion Lung CancerActionable insights for personalized care

AI-Pathway Companion focuses on domain expertise ​in the field of oncology and follows, deeply embedded in his DNA, a multi-disease approach along the entire patient journey. The infrastructure layer with its patient data model allows for horizontal integration of patient information​. The ​technology​ enables easy scaling along different oncology pathways and supports physicians in their daily decision-making.

Through ongoing development and refinement of data interfaces, we aim to increase the number of disease parameters captured throughout the clinical pathway, thereby expanding the relevant data points with the goal of advancing cancer care. We are looking forward to partnering with even more healthcare institutions on optimizing the AI-Pathway Companion solution to their routine clinical practice and preferred lung cancer workflow.

In 2020 we officially presented our first CE-marked pathway – Prostate Cancer3. Now we are expanding the portfolio and we are introducing the AI-Pathway Companion for non-small cell lung cancer2. The solution is all about enabling personalized and standardized decision-making along care pathways. Our mission remains clear: to facilitate diagnosis and therapeutic decisions with a clear goal of improving patient outcomes. 

Our tools for this are: 

  1. We are enabling advanced oncology care through smart integration of disease-specific, longitudinal data for comprehensive and contextualized decision-making
  2. Facilitate accessibility and adherence to evidence-based standards of care to provide transparency and clinical excellence in oncology
  3. Empowering patient-centered care by leveraging personalized and intelligent insights for well-informed shared decision-making


Lung cancer is the most diagnosed cancer (11.6% of the total cases) and the leading cause of cancer death (18.4% of the total cancer deaths) among men and women combined4.

Clinical Use

AI-Pathway Companion

AI-Pathway Companion facilitates standardized tumor board preparation and efficient collaboration across specialities

  1. A significant aspect of cancer care is the challenge of preparing and conducting MDTs.
  2. Data is distributed across multiple systems and cannot be easily aggregated or integrated.
  3. The goal is to better capture, organize, and present essential information and to enable advanced analytics and workflow optimizations. 
  4. This can be achieved via digitalization of workflow and standardization of case reviews in a single dashboard accessible by all MDT members. 

Features and Benefits